Should I buy or sell Fennec Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares. View FENC analyst ratings or view top-rated stocks .

What is Fennec Pharmaceuticals' stock price target for 2024?

3 brokers have issued twelve-month price objectives for Fennec Pharmaceuticals' shares. Their FENC share price targets range from $16.00 to $18.00. On average, they predict the company's share price to reach $17.33 in the next year. This suggests a possible upside of 85.6% from the stock's current price. View analysts price targets for FENC or view top-rated stocks among Wall Street analysts .

How have FENC shares performed in 2024?

Fennec Pharmaceuticals' stock was trading at $11.22 at the start of the year. Since then, FENC stock has decreased by 16.8% and is now trading at $9.34. View the best growth stocks for 2024 here .

Are investors shorting Fennec Pharmaceuticals?

Fennec Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,810,000 shares, an increase of 7.1% from the March 15th total of 1,690,000 shares. Based on an average trading volume of 110,600 shares, the days-to-cover ratio is presently 16.4 days. Currently, 9.1% of the shares of the stock are sold short. View Fennec Pharmaceuticals' Short Interest .

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our FENC earnings forecast .

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by $0.12. The firm earned $9.74 million during the quarter, compared to analyst estimates of $9.47 million.

What guidance has Fennec Pharmaceuticals issued on next quarter's earnings?

Fennec Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20.7 million-$21.2 million, compared to the consensus revenue estimate of $19.6 million.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX) , Sorrento Therapeutics (SRNE) , Pfizer (PFE) , Amarin (AMRN) , VBI Vaccines (VBIV) , Gilead Sciences (GILD) , Trevena (TRVN) , Aldeyra Therapeutics (ALDX) , Coherus BioSciences (CHRS) and Exelixis (EXEL) .

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FENC

Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free FENC Stock Alerts

$9.34

-0.23 (-2.40%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.18
▼
$9.66
50-Day Range: $8.82
▼
$11.12
52-Week Range: $6.30
▼
$11.92

Volume: 143,207 shs
Average Volume: 111,209 shs
Market Capitalization: $253.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.33

Get Fennec Pharmaceuticals alerts:

Fennec Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 85.6% Upside
$17.33 Price Target
Short Interest: Bearish
9.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.24
Based on 9 Articles This Week
Insider Trading: Selling Shares
$1.55 M Sold Last Quarter
Proj. Earnings Growth: 536.36%
From $0.11 to $0.70 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

489th out of 911 stocks

Biological Products, Except Diagnostic Industry

74th out of 150 stocks

3.5

Analyst's Opinion

Consensus Rating
Fennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Fennec Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.07% of the float of Fennec Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Fennec Pharmaceuticals has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Fennec Pharmaceuticals has recently increased by 7.10%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Fennec Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Fennec Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FENC.

2.4

News and Social Media Coverage

News Sentiment
Fennec Pharmaceuticals has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Fennec Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
1 people have searched for FENC on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,548,103.00 in company stock.
Percentage Held by Insiders
11.25% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Fennec Pharmaceuticals are expected to grow by 536.36% in the coming year, from $0.11 to $0.70 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fennec Pharmaceuticals is -15.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fennec Pharmaceuticals is -15.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Fennec Pharmaceuticals Stock (NASDAQ:FENC)

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FENC Stock News Headlines

April 19, 2024 | insidertrades.com

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $220,220.02 in Stock

April 18, 2024 | insidertrades.com

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $228,886.60 in Stock

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 6, 2024 | insidertrades.com

Insider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells 44,300 Shares of Stock

April 5, 2024 | insidertrades.com

Rosty Raykov Sells 40,584 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

March 28, 2024 | insidertrades.com

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $23,190.58 in Stock

March 26, 2024 | insidertrades.com

Fennec Pharmaceuticals Inc (NASDAQ:FENC) CFO Sells $153,725.00 in Stock

April 19, 2024 | americanbankingnews.com

Adrian Haigh Sells 22,222 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 16, 2024 | americanbankingnews.com

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Short Interest Update

April 9, 2024 | finance.yahoo.com

Those who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%

April 7, 2024 | uk.investing.com

Fennec Pharmaceuticals CEO sells shares worth over $950k

April 4, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial Outlook

March 27, 2024 | finance.yahoo.com

Chief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC)

March 26, 2024 | finance.yahoo.com

Chief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC)

March 22, 2024 | markets.businessinsider.com

Buy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion Potential

March 22, 2024 | finance.yahoo.com

Q4 2023 Fennec Pharmaceuticals Inc Earnings Call

March 21, 2024 | investorplace.com

FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023

March 21, 2024 | globenewswire.com

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

March 19, 2024 | bizjournals.com

RTP firm inks licensing deal for European drug launch

March 19, 2024 | globenewswire.com

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

March 17, 2024 | globenewswire.com

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

March 16, 2024 | finance.yahoo.com

FENC Apr 2024 12.500 call

March 14, 2024 | msn.com

Nearly 1,000 Family Dollar stores are closing, owner Dollar Tree announces

March 13, 2024 | nz.finance.yahoo.com

'Milli Vanilli' Review: A Captivating and Moving Documentary

March 13, 2024 | finance.yahoo.com

Analysts Are Optimistic We'll See A Profit From Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

March 6, 2024 | seekingalpha.com

Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price

See More Headlines

Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:FENC
CUSIP: N/A
CIK: 1211583
Web: www.fennecpharma.com
Phone: 919-636-4530
Fax: 919-890-0490
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.33
High Stock Price Target: $18.00
Low Stock Price Target: $16.00
Potential Upside/Downside: +86.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 84.55
P/E Growth: N/A
Net Income: $-16,050,000.00
Net Margins: -75.50%
Pretax Margin: -75.52%
Return on Equity: N/A
Return on Assets: -73.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.56
Quick Ratio: 3.27

Sales & Book Value

Annual Sales: $21.25 million
Price / Sales: 11.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.43) per share
Price / Book: -21.63

Miscellaneous

Outstanding Shares: 27,100,000
Free Float: 24,056,000
Market Cap: $252.03 million
Optionable: Optionable
Beta: 0.38

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Rostislav Raykov (Age 42)
Pres, CEO & Director
Mr. Robert C. Andrade (Age 43)
Chief Financial Officer
Mr. Mark Gowland
Controller
Mr. Lei Fang
Pres of Pharstat Inc
Ms. Anne McKay (Age 64)
Regulatory Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FENC Stock Analysis - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings or view top-rated stocks.
What is Fennec Pharmaceuticals' stock price target for 2024?: 3 brokers have issued twelve-month price objectives for Fennec Pharmaceuticals' shares. Their FENC share price targets range from $16.00 to $18.00. On average, they predict the company's share price to reach $17.33 in the next year. This suggests a possible upside of 85.6% from the stock's current price.
View analysts price targets for FENC or view top-rated stocks among Wall Street analysts.
How have FENC shares performed in 2024?: Fennec Pharmaceuticals' stock was trading at $11.22 at the start of the year. Since then, FENC stock has decreased by 16.8% and is now trading at $9.34.
View the best growth stocks for 2024 here.
Are investors shorting Fennec Pharmaceuticals?: Fennec Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,810,000 shares, an increase of 7.1% from the March 15th total of 1,690,000 shares. Based on an average trading volume of 110,600 shares, the days-to-cover ratio is presently 16.4 days. Currently, 9.1% of the shares of the stock are sold short.
View Fennec Pharmaceuticals' Short Interest.
When is Fennec Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FENC earnings forecast.

How were Fennec Pharmaceuticals' earnings last quarter?: Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of $0.02 by $0.12. The firm earned $9.74 million during the quarter, compared to analyst estimates of $9.47 million.
What guidance has Fennec Pharmaceuticals issued on next quarter's earnings?: Fennec Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20.7 million-$21.2 million, compared to the consensus revenue estimate of $19.6 million.
What other stocks do shareholders of Fennec Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).
How do I buy shares of Fennec Pharmaceuticals?: Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FENC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial